生物活性
PF-03716556 is a potent, and selective acid pump antagonist with pIC50 of 6.026, 6.038 and 6.009 at pH 6.4 for the inhibition of H+/K+-ATPase activity of porcine, canine and human ion-leaky membrane vesicles, respectively. PF-03716556 is used for the treatment of gastroesophageal reflux disease. PF-03716556 is highly selective for H+, K+-ATPase in vitro. PF-03716556 displays no activity at Na+, K+-ATPase. PF-03716556 inhibits gastric acid secretion in rat and dog models. PF-03716556 has no species differences among the porcine, canine and human enzymes. PF-03716556 produced greater inhibition than revaprazan in both the in vitro (ion-tight assay) and in vivo conditions. PF-03716556 offers long-lasting and maximal efficacy within 30 min of a single dosing with responses that are maintained for at least 5 days of repeated dosing with no signs of tolerance. PF-03716556 did not exhibit any biologically relevant activity against any of the tested more than 50 (e.g., adenosine receptor) receptors, ion channels, or enzymes expressed in naive tissues, cell lines and transfectants.
化学数据
分子量 |
394.47 |
分子式 |
C22H26N4O3 |
CAS号 |
928774-43-0 |
纯度 |
>98% |
溶解性(25°C) |
DMSO 70 mg/mL |
储存和运输条件 |
固体粉末: -20°C 冷藏长期储存 常温运输及临时存放 |
实验操作来自于公开的文献,仅供相同实验参考(如实验材料、目的不同,请参考其他文献)
动物实验 |
动物模型 |
rat |
配制 |
5% DMSO and 15% Cremophor EL |
剂量 |
1–10 mg/kg; 1 ml/kg |
给药处理 |
i.v. |
不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)
|
小鼠 |
大鼠 |
兔 |
豚鼠 |
仓鼠 |
狗 |
重量 (kg) |
0.02 |
0.15 |
1.8 |
0.4 |
0.08 |
10 |
体表面积 (m2) |
0.007 |
0.025 |
0.15 |
0.05 |
0.02 |
0.5 |
Km系数 |
3 |
6 |
12 |
8 |
5 |
20 |
动物 A (mg/kg) = 动物 B (mg/kg) × |
动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
储备液配制
以下数据基于半岛bd体育手机客户端 分子量,对于特殊半岛bd体育手机客户端 ,请参照COA中的储备液配制条件和说明进行操作。
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
2.535 mL |
12.6752 mL |
25.3505 mL |
5 mM |
0.507 mL |
2.535 mL |
5.0701 mL |
10 mM |
0.2535 mL |
1.2675 mL |
2.535 mL |